« Back
A Look into Antibody–drug conjugates (ADCs) Targets
Poster Title: A Look into Antibody–drug conjugates (ADCs) Targets
Submitted on 08 Aug 2022
Author(s): Sally Zou
Affiliations: Hunan Huateng Pharmaceutical Co. Ltd.
Poster Views: 100
View poster »

Poster Information
Abstract: Antibody-drug conjugates (ADCs) combine the advantages of high targeting of antibody drugs and high activity of Payload in tumor tissues, providing better efficacy than traditional antibody-based therapeutic agents and demonstrating great clinical value.

ADC has become another popular field after the immune checkpoint inhibitors represented by PD-1/PD-L1, and companies need to speed up the R&D progress in order to seize the first-mover advantage. Reasonable selection of targets is crucial if companies want to survive or even stand out.

R&D Status of ADCs
Currently, there are over 100 ADC drugs in various stages of development worldwide, of which 14 have been approved for marketing, a dozen have entered clinical phase III, and most are still in clinical phase I and preclinical stages.

Among the 14 approved ADC drugs, 7 are for the treatment of hematological tumors and 7 are for the treatment of solid tumors. There are 11 targets involved, namely CD33, CD30, HER2, TROP2, BCMA, EGFR, CD19, CD22, CD79b, Nectin-4 and TF, with three targeting HER2 and two targeting CD22. The overall global market for ADC drugs has exceeded US$5 billion in 2021.
Summary: Approved ADC drugs list and the ongoing trails with hot ADC targets such as HER2, EGFR, TROP2, FRα, CLDN18.2,, c-Met, Nectin-4 and TF, with three targeting HER2 and two targeting CD22. References: 1. Fu, Z., Li, S., Han, S. et al. Antibody drug conjugate: the “biological missile” for targeted cancer therapy. Sig Transduct Target Ther 7, 93 (2022).
2. Ferraro, E., Drago, J.Z. & Modi, S. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions. Breast Cancer Res 23, 84 (2021).
3. Yu J, Fang T, Yun C, Liu X, Cai X. Antibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor Family in Cancers. Front Mol Biosci. 2022 Feb 28;9:847835. doi: 10.3389/fmolb.2022.847835. PMID: 35295841; PMCID: PMC8919033.
4. Cao, W., Xing, H., Li, Y. et al. Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy. Biomark Res 10, 38 (2022).
5. Scaranti, M., Cojocaru, E., Banerjee, S. et al. Exploiting the folate receptor α in oncology. Nat Rev Clin Oncol 17, 349–359 (20
Report abuse »
Ask the author a question about this poster.
Ask a Question »

Creative Commons